FindTrial
Sign In

MM-151

DRUG3 trials

Sponsors

Merrimack Pharmaceuticals

Conditions

Advanced Solid TumorsColorectal CancerNon Small Cell Lung CancerNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckSquamous Cell Head and Neck CancerTriple Negative Breast Cancer

Phase 1

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
CompletedNCT01520389
Merrimack PharmaceuticalsAdvanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer +2
Start: 2012-01-31End: 2016-01-31Updated: 2018-03-21
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
TerminatedNCT02538627
Merrimack PharmaceuticalsColorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Start: 2015-08-31End: 2016-10-05Updated: 2017-09-05
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
WithdrawnNCT02785068
Merrimack PharmaceuticalsColorectal Cancer
Start: 2016-07-31End: 2018-10-31Updated: 2017-01-11

Related Papers

Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.
Journal of Clinical Oncology2016-05-201 citations
A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.
Journal of Clinical Oncology2016-05-201 citations
Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.
Journal of Clinical Oncology2015-01-207 citations
Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors.
Journal of Clinical Oncology2014-05-207 citations